Innovation in coronary artery disease and heart failure: Clinical benefits of pure heart rate reduction with ivabradine

Annals of the New York Academy of Sciences

Volumn 1222, Issue 1, 2011, Pages 90-99

  Canet, Emmanuel ^a   Lerebours, Guy ^a   Vilaine, Jean Paul ^b  

^a IRIS Institut de Recherches Internationales Servier   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Angina; Coronary artery disease; Heart failure; Heart rate; Ivabradine

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE; PLACEBO;

ANGINA PECTORIS; ARTICLE; BRADYCARDIA; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; MONOTHERAPY; NONHUMAN; PROGNOSIS;

ANGINA;

EID: 79952848474     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05960.x     Document Type: Article

References (42)

1. Fox, K., J.S. Borer, A.J. Camm, et al 2007. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol. 50: 823-830.
2. Andrews, T.C., T. Fenton, N. Toyosaki, et al 1993. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 88: 92-100.
3. Kop, W.J., R.J. Verdino, J.S. Gottdiener, et al 2001. Changes in heart rate and heart rate variability before ambulatory ischemic events(1). J. Am. Coll. Cardiol. 38: 742-749.
4. Jouven, X., J.P. Empana, P.J. Schwartz, et al 2005. Heart-rate profile during exercise as a predictor of sudden death. N. Engl. J. Med. 352: 1951-1958.
5. Mensink, G.B. & H. Hoffmeister 1997. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur. Heart. J. 18: 1404-1410.
6. Hjalmarson, A., E.A. Gilpin, J. Kjekshus, et al 1990. Influence of heart rate on mortality after acute myocardial infarction. Am. J. Cardiol. 65: 547-553.
7. Kolloch, R., U.F. Legler, A. Champion, et al 2008. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur. Heart. J. 29: 1327-1334.
8. Fox, K., I. Ford, P.G. Steg, et al 2008. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372: 817-821.
9. Bohm, M., K. Swedberg, M. Komajda, et al 2010. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet 376: 886-894.
10. Lechat, P., J.S. Hulot, S. Escolano, et al 2001. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103: 1428-1433.
11. Cucherat, M. 2007. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur. Heart. J. 28: 3012-3019.
12. Flannery, G., R. Gehrig-Mills, B. Billah, et al 2008. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am. J. Cardiol. 101: 865-869.
13. McAlister, F.A., N. Wiebe, J.A. Ezekowitz, et al 2009. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med. 150: 784-794.
14. Ceconi, C., L. Comini, S. Suffredini, et al 2011. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am. J. Physiol. Heart. Circ. Physiol. 300: H366-H373.
15. Swedberg, K., M. Komajda, M. Bohm, et al 2010. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 376: 875-885.
16. Brown, H.F., D. DiFrancesco & S.J. Noble 1979. How does adrenaline accelerate the heart? Nature 280: 235-236.
17. DiFrancesco, D. Pacemaker mechanisms in cardiac tissue. 1993. Annu. Rev. Physiol. 55: 455-472.
18. Borer, J.S. & J.Y. Heuzey 2008. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am. J. Ther. 15: 461-473.
19. Thollon, C., C. Cambarrat, J. Vian, et al 1994. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br. J. Pharmacol. 112: 37-42.
20. Bois, P., J. Bescond, B. Renaudon & J. Lenfant 1996. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br. J. Pharmacol. 118: 1051-1057.
21. Camm, A.J. & C.P. Lau 2003. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs. R. D. 4: 83-89.
22. Simon, L., B. Ghaleh, L. Puybasset, et al 1995. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J. Pharmacol. Exp. Ther. 275: 659-666.
23. Vilaine, J.P., J.P. Bidouard, L. Lesage, et al 2003. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J. Cardiovasc. Pharmacol. 42: 688-696.
24. Colin, P., B. Ghaleh, X. Monnet, et al 2003. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am. J. Physiol. Heart. Circ. Physiol. 284: H676-H682.
25. Ceconi, C., A. Cargnoni, G. Francolini, et al 2009. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc. Res. 84: 72-82.
26. Heusch, G., A. Skyschally, P. Gres, et al 2008. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur. Heart. J. 29: 2265-2275.
27. Mulder, P., S. Barbier, A. Chagraoui, et al 2004. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109: 1674-1679.
28. Borer, J.S., K. Fox, P. Jaillon & G. Lerebours 2003. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107: 817-823.
29. Tardif, J.C., I. Ford, M. Tendera, et al 2005. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur. Heart. J. 26: 2529-2536.
30. Colin, P., B. Ghaleh, X. Monnet, et al 2004. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J. Pharmacol. Exp. Ther. 308: 236-240.
31. Ruzyllo, W., M. Tendera, I. Ford & K.M. Fox 2007. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 67: 393-405.
32. Lopez-Bescos, L., S. Filipova & R. Martos 2007. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology 108: 387-396.
33. Tardif, J.C., P. Ponikowski & T. Kahan 2009. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur. Heart. J. 30: 540-548.
34. Summary of product characteristics. Procoralan European Medicines Agency. Available at: Accessed: 23-11-2010.
35. Tendera, M., J. Borer & J. Tardif 2009. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology 114: 116-125.
36. Fox, K., I. Ford, P.G. Steg, et al 2008. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372: 807-816.
37. Fox, K., I. Ford, P.G. Steg, et al 2009. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart. J. 30: 2337-2345.
38. Heidland, U.E. & B.E. Strauer 2001. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104: 1477-1482.
39. Drouin, A., M.E. Gendron, E. Thorin, et al 2008. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br. J. Pharmacol. 154: 749-757.
40. Custodis, F., M. Baumhakel, N. Schlimmer, et al 2008. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117: 2377-2387.
41. Fox, K. 2010. Ivabradine: advantages throughout the cardiovascular continuum. Eur. Heart. J. Suppl. 12:C16-C20.
42. Dickstein, K., A. Cohen-Solal, G. Filippatos, et al 2008. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart. Fail. 10: 933-989.